Table 1.
Baseline comparison of children randomized to daily and three times a week dosing schedule.
| Baseline characteristics |
Daily (n = 128) |
Three times a week (n = 148) |
Total (n = 276) |
P* Value |
| Sex (%) | ||||
| Male | 57.0 | 55.4 | 56.3 | 0.81 |
| Age (months) | 0.45 | |||
| Median | 29.7 | 21.8 | 25.9 | |
| (IQR) | (13.1 to 47.7) | (10.2 to 52.6) | (11.9 to 51.0) | |
| Age (years; %) | 0.50 | |||
| < 1 year | 23.4 | 26.4 | 25.0 | |
| 1-4 years | 51.6 | 44.6 | 47.8 | |
| > 4 years | 25.0 | 29.0 | 27.1 | |
| Study drug (%) | 0.39 | |||
| Placebo | 35.2 | 40.5 | 38.0 | |
| Isoniazid | 64.8 | 59.5 | 62.1 | |
| Site (%) | 0.55 | |||
| RCCH | 52.3 | 48.0 | 50.0 | |
| TCH | 47.7 | 52.0 | 50.0 | |
| CDC clinical stage (%) | 0.95 | |||
| N or A | 14.8 | 13.5 | 14.1 | |
| B | 65.6 | 66.9 | 66.3 | |
| C | 19.5 | 19.6 | 19.6 | |
| CDC immune stage (%) | 0.09 | |||
| 1 | 22.7 | 34.5 | 29.0 | |
| 2 | 46.1 | 37.2 | 41.3 | |
| 3 | 31.2 | 28.4 | 29.7 | |
| On HAART at randomization (%) | 10.9 | 9.5 | 10.1 | 0.7 |
| Started HAART during study (%) | 64.8 | 58.8 | 61.6 | 0.32 |
| No tap water in house (%) | 50.0 | 53.7 | 52.2 | 0.63 |
| No electricity in house (%) | 16.5 | 23.7 | 20.3 | 0.18 |
| No flush toilet in house (%) | 55.1 | 56.8 | 56.0 | 0.81 |
| Not a brick house (%) | 41.7 | 45.6 | 43.8 | 0.54 |
| Number of people living in house | 0.5 | |||
| Med | 5 | 5 | 5 | |
| (IQR) | (3 to 6) | (4 to 6.5) | (3 to 6) | |
| Number of people in house (%) | 0.31 | |||
| ≤ 5 | 67.7 | 61.5 | 64.4 | |
| > 5 | 32.3 | 38.5 | 35.6 | |
Figures are medians (interquartile range) for continuous variables and percentage of children for categorical variables.
* P-values from Fisher's exact test for categorical data or two-sample Wilcoxon rank-sum (Mann-Whitney) test for continuous data
RCCH = Red Cross War Memorial Children's Hospital; TCH = Tygerberg Children's Hospital; CDC = Centers for Disease Control and Prevention; HAART = highly active antiretroviral therapy.